Susquehanna initiates coverage on Simcere Pharmaceutical Group (NYSE: SCR) with a Neutral.

Susquehanna analyst says, "SCR delivered ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE